骨髓纤维化
危险分层
干细胞
医学
造血干细胞移植
分层(种子)
造血
肿瘤科
造血细胞
重症监护医学
造血干细胞
内科学
移植
癌症研究
免疫学
生物
遗传学
骨髓
种子休眠
发芽
植物
休眠
作者
Haris Ali,Andrea Bacigalupo
摘要
Abstract Background Allogeneic hemopoietic stem cell transplantation (HSCT) currently remains the only curative treatment for patients with myelofibrosis (MF). Transplant related mortality (TRM) and relapse, remain two significant complications which need to be addressed. Aims The aim of this manuscript is to review current available reports on changes which have recently occurred, to improve the outcome of MF patients undergoing an allogeneic HSCT. Methods Published papers were used to analyze different aspects of allogeneic HSCT. Results Changes and updates are provided on selection of patients, prognostic systems, managing splenomegaly, conditioning regimens, predicting transplant outcome, stem cell sources, stem cell donors, graft versus host disease (GvHD) prophylaxis, patients with blast phase, hematopoietic reconstitution, disease markers, donor chimerism, and treatment of relapse. Conclusions The review outlines new transplant platforms which are now available for patients with myelofibrosis, together with persisting problems, among which, older age combined with marrow fibrosis and an inflammatory disease. Relapse also requires aggressive monitoring of drivers mutations, and early cellular therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI